Sangamo Therapeutics, Inc.
SGMO
$0.5863
$0.01312.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.31M | 6.44M | 7.55M | 49.41M | 356.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.31M | 6.44M | 7.55M | 49.41M | 356.00K |
| Cost of Revenue | 27.08M | 24.81M | 23.68M | 27.73M | 24.22M |
| Gross Profit | -8.78M | -18.37M | -16.12M | 21.68M | -23.87M |
| SG&A Expenses | 9.08M | 10.06M | 9.77M | 8.65M | 12.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.16M | 34.87M | 33.44M | 36.38M | 36.27M |
| Operating Income | -17.86M | -28.43M | -25.89M | 13.03M | -35.91M |
| Income Before Tax | -19.96M | -30.48M | -23.82M | 10.76M | -36.05M |
| Income Tax Expenses | 27.00K | 119.00K | -427.00K | 88.00K | 74.00K |
| Earnings from Continuing Operations | -19.99M | -30.60M | -23.40M | 10.67M | -36.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.99M | -30.60M | -23.40M | 10.67M | -36.13M |
| EBIT | -17.86M | -28.43M | -25.89M | 13.03M | -35.91M |
| EBITDA | -16.86M | -27.41M | -24.65M | 14.25M | -34.67M |
| EPS Basic | -0.08 | -0.14 | -0.11 | 0.05 | -0.18 |
| Normalized Basic EPS | -0.05 | -0.08 | -0.07 | 0.04 | -0.11 |
| EPS Diluted | -0.08 | -0.14 | -0.12 | 0.04 | -0.18 |
| Normalized Diluted EPS | -0.05 | -0.08 | -0.07 | 0.04 | -0.11 |
| Average Basic Shares Outstanding | 256.95M | 220.27M | 210.19M | 208.35M | 203.95M |
| Average Diluted Shares Outstanding | 256.95M | 220.27M | 210.19M | 214.33M | 203.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |